4-(2,5-dioxo-imidazolidin-1-ylmethyl)-benzaldehyde | 1246250-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4-(2,5-dioxo-imidazolidin-1-ylmethyl)-benzaldehyde
• 英文别名: 3-(4-Formylbenzyl)hydantoin；4-[(2,5-dioxoimidazolidin-1-yl)methyl]benzaldehyde
• CAS: 1246250-68-9
• 化学式: C₁₁H₁₀N₂O₃
• 分子量: 218.212
• InChiKey: PMLMWTWOCBIDEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  66.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氨基-4,6-二甲氧基苯甲酰胺 、 4-(2,5-dioxo-imidazolidin-1-ylmethyl)-benzaldehyde 在 对甲苯磺酸 、 sodium hydrogensulfite 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 17.0h， 以46%的产率得到3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)benzyl)imidazolidine-2,4-dione
  参考文献：
  名称：

  Anti-inflammatory agents

  摘要：

  揭示了一种新型化合物，可用于调节白细胞介素-6（IL-6）和/或血管细胞粘附分子-1（VCAM-1）的表达，并且它们在治疗和/或预防心血管和炎症性疾病以及相关疾病状态中的用途，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化、牛皮癣和炎症性肠病以及自身免疫疾病。此外，还揭示了包含这些新型化合物的组合物，以及它们的制备方法。

  公开号：

  US09238640B2
• 作为产物：
  描述：

  海因 、 4-溴甲基苯甲醛 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 63.0h， 以64%的产率得到4-(2,5-dioxo-imidazolidin-1-ylmethyl)-benzaldehyde
  参考文献：
  名称：

  TREATMENT OF DISEASES BY EPIGENETIC REGULATION

  摘要：

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防对BET抑制剂易感的疾病或疾病。

  公开号：

  US20130281399A1

文献信息

• TREATMENT OF DISEASES BY EPIGENETIC REGULATION
  申请人：McLure Kevin G.

  公开号：US20130281399A1

  公开（公告）日：2013-10-24

  The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

  本公开提供了抑制溴结构域和额外末端结构域（BET）蛋白的非天然存在的多酚化合物。所公开的组合物和方法可用于治疗和预防对BET抑制剂易感的疾病或疾病。
• Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US06667334B1

  公开（公告）日：2003-12-23

  The present invention relates to imidazolidine derivatives of the formula I, in which B, E, W, Y, R, R2, R3, R30, e and h have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of diseases which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use, in particular as pharmaceutical active compounds, and pharmaceutical preparations which contain compounds of the formula I.

  本发明涉及式I的咪唑啉衍生物，其中B、E、W、Y、R、R2、R3、R30、e和h具有所述权利要求中指示的含义。公式I的化合物是有价值的药物活性化合物，例如适用于治疗和预防炎症性疾病，例如类风湿性关节炎或过敏性疾病。公式I的化合物是白细胞黏附和迁移的抑制剂和/或属于整合素组的黏附受体VLA-4的拮抗剂。它们通常适用于由白细胞黏附和/或白细胞迁移的不良程度引起或与之相关的疾病的治疗或预防，或者在其中基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用发挥作用。本发明还涉及制备公式I化合物的方法，它们的使用，特别是作为药物活性化合物，以及含有公式I化合物的药物制剂。
• NOVEL ANTI-INFLAMMATORY AGENTS
  申请人：Hansen Henrik C.

  公开号：US20120040954A1

  公开（公告）日：2012-02-16

  Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

  本发明涉及一种新型化合物，该化合物可用于调节白细胞介素-6（IL-6）和/或血管细胞黏附分子-1（VCAM-1）的表达，并且可用于治疗和/或预防心血管和炎症性疾病及相关疾病状态，例如动脉粥样硬化、哮喘、关节炎、癌症、多发性硬化症、牛皮癣和炎症性肠病以及自身免疫疾病。此外，本发明还涉及包含该新型化合物的组合物，以及其制备方法。
• ANTI-INFLAMMATORY AGENTS
  申请人：Resverlogix Corp.

  公开号：US20210070716A1

  公开（公告）日：2021-03-11

  Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.
• US6667334B1
  申请人：——

  公开号：US6667334B1

  公开（公告）日：2003-12-23